ArticleDrug design, development and therapy2018
Preliminary study on conjugation of formononetin with multiwalled carbon nanotubes for inducing apoptosis via ROS production in HeLa cells.
Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 24 citations in OpenAlex.
- Using the Cocrystal Approach as a Promising Drug Delivery System to Enhance the Dissolution and Bioavailability of Formononetin Using an Imidazole Coformer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Potential Therapeutic Targets of Formononetin, a Type of Methoxylated Isoflavone, and Its Role in Cancer Therapy through the Modulation of Signal Transduction Pathways.International journal of molecular sciences · 2023Review
- Parent-Metabolite Pharmacokinetic Modeling of Formononetin and Its Active Metabolites in Rats after Oral Administration of Formononetin Formulations.Pharmaceutics · 2022Article
- Potential Mechanisms of Plant-Derived Natural Products in the Treatment of Cervical Cancer.Biomolecules · 2021Review
- Review
- Formononetin: A Review of Its Anticancer Potentials and Mechanisms.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present work was conducted to prepare and evaluate multiwalled carbon nanotube-formononetin (MWCNT-FMN) composite for sustained delivery and inducing apop-tosis via reactive oxygen species (ROS) production in HeLa cells.
methodsThe composite was prepared by solution mixing with short carboxylic group-functionalized multiwalled carbon nanotubes (MWCNT-COOH). Then the composite was characterized by laser particle size analysis, Fourier transform infrared spectrometry, X-ray diffractometry, differential scanning calorimetry, and scanning electron microscopy. Drug release rates in vitro were determined by dialysis method. The in vitro cytotoxicity study was performed using water soluble tetrazolium assay. The cellular apoptosis assay, ROS, and mitochondrial membrane potential (MMP) of HeLa cells were investigated by acridine orange and ethidium bromide double dye, 2',7'-dichlorodihydrofluorescein diacetate, and 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide probe, respectively.
resultsThe entrapment efficiency was 28.77%±0.15%, and the loading capacity was 12.05%±0.20%. The release of MWCNT-FMN was sustained, and the cumulative release rate of formononetin (FMN) from MWCNT-COOH was higher at pH 7.4 than at pH 5.3. The in vitro cytotoxicity assay demonstrated that FMN, MWCNT-COOH, and MWCNT-FMN had no significant effects on the proliferation and viability of mouse fibroblast 3T3 cells over 48 hours, while the cell growth inhibition of the three samples showed concentration-dependent for HeLa cells. Biological assay suggested FMN and MWCNT-FMN could induce apoptosis in HeLa cells, meanwhile the cells exhibited stronger ROS signal and more depolarized MMP than that of the control group.
conclusionThese results preliminarily demonstrated that MWCNT-FMN exerted anticancer efficacy through cellular apoptosis induced by ROS-mediated mitochondrial dysfunctions in HeLa cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.